Table 2.

Proportional hazards regression models for ARIA-E associated with bapineuzumab

Factor	Level	Univariate Models HR (95% CI) (P value)	Full Model HR (95% CI) (P value)	Reduced Model HR (95% CI) (P value)
Dose
	0·15 mg/kg	1·00 (referent)	1·00 (referent)	1·00 (referent)
	0·5 mg/kg	1·76 (0·44, 7·03) (0·43)	1·76 (0·43, 7·23) (0·43)	2·00 (0·50, 8·04) (0·33)
	1·0 m/kg	3·40 (0.97, 11·85) (0·06)	3·13 (0·89, 10·95) (0·07)	3·13 (0·89, 10·94) (0·07)
	2·0 mg/kg	5·60 (1·58, 19·88) (<0·01)	6·83 (1·89, 24·62) (<0·01)	6·80 (1·90, 24·33) (<0·01)
APOE ε4 genotype
	No alleles	1·00 (referent)	1·00 (referent)	1·00 (referent)
	Heterozygote	3·07 (1·14, 8·27) (0·03)	3·62 (1·30, 10·08) (0·01)	3·80 (1·38, 10·51) (0·01)
	Homozygote	6·87 (2·42, 19·53) (<0·01)	7·28 (2·53, 20·95) (<0·01)	7·15 (2·50, 20·48) (<0·01)
White matter hyperintensities
	confluent or diffusion lesions vs. none or punctuate	1·65 (0·68, 3·97 (0·27)	1·75 (0·69, 4·43) (0·24)
Small hemosiderin deposits
	present (one or more) vs. absent (none)	1·24 (0·44, 3·50) (0·69)	1·32 (0·45, 3·88) (0·61)

All factors are analyzed as categorical variables. Univariate Models: each factor is alone in the model. Full Model: all factors are in the model; thus, each factor may be considered adjusted for the other factors. Reduced Model: only the factors in which the lower 95% CI exceeded 10 in at least one stratum, specifically dose and APOE ε4 genotype. ARIA-E, amyloid-related imaging abnormalities thought to represent parenchymal vasogenic edema and sulcal effusions; ApoE ε4, apolipoprotein E epsilon 4 allele frequency; CI, confidence interval; HR, hazard ratio; APOE ε4 = apolipoprotein E epsilon 4 allele frequency. These analyses were performed on a subset of data with complete information on all four factors, total subjects n= 204, ARIA-E events n = 35; hence the number of subjects differs slightly from that in the descriptive summary found in Table 1.